The objective of this study is to evaluate potential relationships between gene copy numbers for PIK3CA (the catalytic subunit of PI3K), PTEN and EGFR, and outcomes for NSCLC patients treated with gefitinib. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.